<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00591136</url>
  </required_header>
  <id_info>
    <org_study_id>IBL1001</org_study_id>
    <nct_id>NCT00591136</nct_id>
  </id_info>
  <brief_title>Phase I Study of Indibulin in Patients With Solid Tumors</brief_title>
  <official_title>Dose-finding and Pharmacokinetic Trial of Orally Administered D-24851 to Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziopharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ziopharm</source>
  <brief_summary>
    <textblock>
      Dose-finding and pharmacokinetic trial of orally administered Indibulin to patients with&#xD;
      solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>toxicities</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indibulin</intervention_name>
    <description>Dose escalation, daily dosing for 14 days every 3 weeks, for up to 4 months</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>ZIO-301</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Male or female patient, &gt;= 18 years of age.&#xD;
&#xD;
          -  Histologically/cytologically proven solid malignant tumor, for which standard&#xD;
             treatment of proven efficacy are not or no longer available.&#xD;
&#xD;
          -  Performance status 0-2 ECOG/WHO.&#xD;
&#xD;
          -  Life expectancy &gt; 3 months.&#xD;
&#xD;
          -  Able and willing to undergo blood sampling for pharmacokinetics.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Safety concerns:&#xD;
&#xD;
          -  Any non-compensated or uncontrolled non-malignant condition, such as, symptomatic&#xD;
             heart failure, active tuberculosis or any other chronic or active infection.&#xD;
&#xD;
          -  History of allergic reaction to one of the ingredients of the trial medication.&#xD;
&#xD;
          -  Clinically relevant abnormality in organ function as evidenced by any of the following&#xD;
             pa¬ra¬meters:&#xD;
&#xD;
          -  White blood cell count: &lt; 3.0 x 109/l ANC: &lt; 1.5 x 109/l&#xD;
&#xD;
          -  Thrombocytes: &lt; 100 x 109/l&#xD;
&#xD;
          -  Hemoglobin &lt; 6.0 mM&#xD;
&#xD;
          -  Bilirubin (total): &gt; 1.5 times upper limit of normal range&#xD;
&#xD;
          -  ASAT, ALAT: &gt; 2.5 times upper limit of normal range unless related to metastases in&#xD;
             which case &gt; 5 times upper normal limit is allowed&#xD;
&#xD;
          -  Creatinine (serum) &gt; 135 µmol/l (&gt; 1.5 mg/100ml) OR&#xD;
&#xD;
          -  Creatinine clearance: &lt; 50 ml/min (calculated according to modified Cockcroft and&#xD;
             Gault)&#xD;
&#xD;
          -  Breast feeding, pregnancy or planned pregnancy. A reliable method of contraception&#xD;
             must be used in men and in women of childbearing potential during the study and for 3&#xD;
             months after last study drug administration.&#xD;
&#xD;
          -  Lack of suitability for the trial:&#xD;
&#xD;
          -  Concomitant treatment with any other investigational drugs or exposure to another&#xD;
             investigational agent within the last 4 weeks prior to study specific screening&#xD;
             procedures (period should be extended if the patient has received any drug which is&#xD;
             known to have de¬layed toxicity or prolonged half-life).&#xD;
&#xD;
          -  Active peptic ulcer or any GI condition that could alter absorption or motility.&#xD;
&#xD;
          -  Chronic use of H2-antagonists or proton pump inhibitors.&#xD;
&#xD;
          -  Any other cancer treatment during the study or administered within the last 4 weeks (6&#xD;
             weeks for nitrosoureas, mitomycin C, high-dose carboplatin or extensive radiotherapy)&#xD;
             before start of study treatment, except irradiation of non-target lesions for symptom&#xD;
             relief and bi-phosphonate treatment of bone metastases.&#xD;
&#xD;
          -  Clinically symptomatic brain metastases or leptomeningeal disease.&#xD;
&#xD;
          -  Neurological or psychiatric disease or drug or alcohol abuse which would interfere&#xD;
             with the patients proper completion of the protocol assignment.&#xD;
&#xD;
          -  Administrative reasons:&#xD;
&#xD;
          -  Anticipated non-availability for study visits/procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Lewis, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ZIOPHARM Oncology, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <last_update_submitted>July 18, 2012</last_update_submitted>
  <last_update_submitted_qc>July 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

